Common GLP-1 side effects may include nausea, diarrhea, vomiting, constipation, stomach pain, headache, fatigue, indigestion, dizziness, bloating, belching, gas, reflux, and low blood sugar, especially in people with type 2 diabetes taking insulin or sulfonylureas
Steady-state typically occurs after four to five consecutive weekly doses, meaning that by week four to five of treatment, each injection adds to residual drug from the previous week rather than building on a low baseline
Thus, it is plausible that GLP1RAs could reduce the burden of cognitive impairment and mental health disorders in the general population [41]
Growing Rates of Metabolic Diseases and Obesity One of the main factors behind the next-generation obesity drug pipeline market is the rapidly rising global burden of obesity